This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Five Dumbest Things on Wall Street This Week: March 1

3.) Vivus Marketing Mess

The sales and marketing folks at Vivus (VVUS - Get Report) better start pulling their weight soon, or the company's market cap is going to slim down in a hurry.

Or should we say, slim down even more!

Shares of the biotech shriveled 12.5% Tuesday after it said sales of the highly anticipated weight loss drug Qsymia totaled $2 million in the latest quarter, a sum that was $1 million short of downgraded analyst consensus. Last fall, in case you forgot, analysts on average were looking for more than $24 million in Qsymia sales during the December quarter.

On the whole, Vivus said it lost $56.7 million, or 56 cents per share, during the fourth quarter compared with a loss of $11.5 million, or 13 cents, last year. Wall Street's pencil-pushers expected a loss of 25 cents per share and $3 million in revenue. For all of 2012, Vivus lost $139.9 million, or $1.42 per share, wider than its net loss of $46.1 million, or 55 cents, in 2011.

Yeah, it was a pretty big miss by any stretch of the imagination both by the company itself, as well as Wall Street's so-called experts. And what makes it all the more painful for everybody involved - except merry-old us of course - is the amount the company spent to ring up that measly sales result.

Vivus shelled out more than $50 million in SG&A to generate those lousy $2 million in Qsymia sales in the fourth quarter. Add in R&D costs and Vivus' total operating expenses topped $58 million.

Holy cow guys! We know there is limited insurance coverage and high copays for this drug. Furthermore, we are well aware the drug is only available through mail order. Nevertheless, that ROI is miniscule given the push Vivus has given this product in the form of free trials and other PR shenanigans.

And according to TheStreet's biotech ax Adam Feuerstein, if Vivus doesn't get more bang for its marketing bucks, the company could wither away by this time next year.

"Vivus ended last year with $213 million in the piggy bank and refused to offer any spending guidance for 2013 except to acknowledge that marketing expenses for Qsymia will remain high. Even if Qsymia sales pick up, Vivus' current and expected rate of spending means there's less than a year's cash remaining," wrote Feuerstein.

If that's the case, Vivus employees better shrink their marketing budget to fit their actual sales figures in a hurry.

Either that or start fattening up their resumes even quicker.

3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AH $0.00 0.00%
AVID $16.15 0.00%
MSO $5.96 0.00%
LYV $25.99 0.00%
VVUS $2.46 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs